vTv Therapeutics to Participate in Upcoming September Investor Conferences
Rhea-AI Summary
vTv Therapeutics (Nasdaq: VTVT), a late-stage biopharmaceutical company developing cadisegliatin for type 1 diabetes treatment, has announced its participation in two major investor conferences in September 2025.
The company will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9, participating in one-on-one investor meetings. On the same day, management will also present at the Morgan Stanley 23rd Annual Global Healthcare Conference, featuring a fireside chat from 2:35 PM to 3:10 PM EST, along with individual investor meetings.
Positive
- None.
Negative
- None.
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:
| H.C. Wainwright 27th Annual Global Investment Conference | |
| Date: | Tuesday, September 9, 2025 |
| Format: | 1x1 Investor Meetings Only |
| Morgan Stanley 23rd Annual Global Healthcare Conference | |
| Date: | Tuesday, September 9, 2025 |
| Format: | Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings |
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
When is vTv Therapeutics (VTVT) presenting at the Morgan Stanley Healthcare Conference 2025?
What conferences is vTv Therapeutics (VTVT) attending in September 2025?
What is vTv Therapeutics' (VTVT) main drug development focus?
What type of meetings will VTVT have at the H.C. Wainwright Conference?
